CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?

(1:26)

Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in RR Multiple Myeloma

(7:3)

Jesus Berdeja | EHA 2018 | Summary of the CRB-401 phase I bb2121 CAR T-cell study

(1:45)

CAR T-cells: targeting BCMA

(1:13)

Early MRD negativity predicts depth of response to CAR T-cells in R/R MM

(2:34)

bb2121: a promising outlook for the future of multiple myeloma

(1:13)

Results from CAR T-cell bb2121 first-in-human trial for R/R MM

(7:6)

CAR T-cell therapy for refractory multiple myeloma

(4:14)

Anti-BCMA CAR T-cells for MM: durable clinical responses with ide-cel (formerly bb2121)

(3:17)

Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Pts w/RR Multiple Myeloma

(6:28)

CAR-T Therapy, CARTITUDE-1 ciltacabtagene autoleucel in RRMM Patients | Yi Lin, MD, PhD | ASCO 2023

(3:27)

Miller Hero: Corey Andolina | Operations Manager – The Miller Group

(1:51)

From bb2121 to bb21217: does bb007 improve efficacy in MM?

(2:40)

Every Blox Fruits Player in a Nutshell:

(15)

Midwest CEPAC Meeting on Treatments for Multiple Myeloma: Public Comments

(24:39)

MM trial highlights from ASCO 2018

(2:34)

COLUMBIA MODEL CRB 101

(1:1econd)

Anti-BCMA CAR T-cells in myeloma: what data do we have so far?

(3:38)

CRB-402 study update: T-cell phenotypes in myeloma

(2:38)